Extended Data Figure 10:

a. Genetic loci for p48-Cre;LSL-KRAS^G12D;p53^fl/+ (KPC) model and treatment scheme for IgG+PBS and CSF1 Ab+CLD followed by cerulein by 6 hourly i.p injections every other day for 5 days. b. Genetic loci for p48-Cre;ROSA26-rtTa-IRES-EGFP;TetO-KRAS^G12D (iKRAS*) model and treatment scheme for IgG+PBS and CSF1 Ab+CLD followed by cerulein by 6 hourly i.p injections on two consecutive days, followed by doxycycline administration in drinking water. c. Representative mIHC images of pancreas tissue from iKRAS* mice treated with IgG+PBS or CSF1 Ab+CLD as in b, stained for hematoxylin, CK19, F4/80, LYVE1, and CD163 (scale bars are 100μM), and quantification of F4/80⁺LYVE1⁺CD163⁺ macrophages, displayed as the percentage of cells; n=7 mice in IgG+PBS group, n=8 mice in CSF1 Ab+CLD group, and *P=0.0003. d. Representative images of pancreas tissue stained for H&E and CK19 from iKRAS* mice treated with IgG+PBS or CSF1 Ab+CLD as in b, scale bars are 100μM. e. Quantification of relative pancreas weight and CK19⁺ cells displayed as percentage of total cells from iKRAS* mice treated with IgG+PBS or CSF1 Ab+CLD as in b; n=7 mice in IgG+PBS group, n=10 mice in CSF1 Ab+CLD group, *P=0.0097 in relative pancreas weight analysis, and *P=0.0250 in CK19 analysis. f. Tumor weight and size measurements of CCR2-WT and CCR2-KO mice orthotopically implanted with the KP2 pancreatic cancer cell line; n=9 mice/group. g. Representative images and quantification of pancreas tissue from CCR2-WT and CCR2-KO mice orthotopically implanted with the KP2 pancreatic cancer cell line stained for podoplanin, scale bars are 100μM; n=9 mice/group. Data are presented as mean ± SEM unless otherwise indicated. n.s., not significant; *p <0.05. For comparisons between two groups, Student’s two-tailed t-test was used.